The concepts of antiretroviral-based treatment as prevention (TasP) and pre-exposure prophylaxis (PrEP) gained formidable ground in 2011, both cited in numerous 2011 Top 10 lists of clinical developments in HIV medicine. However, there is much to learn about and plan for as we prepare for their integration into clinical practice. In addition, there are numerous challenges facing a variety of stakeholders as we seek to achieve the impact these biomedical prevention interventions promise in the third decade of the HIV pandemic.

The International Association of Physicians in AIDS Care (IAPAC) will host an evidence summit entitled, Controlling the HIV Pandemic with Antiretrovirals: Treatment as Prevention and Pre-Exposure Prophylaxis, June 11-12, 2012, at the Royal Garden Hotel in London. The summit’s goal is to provide a venue for the presentation of data related to and discussion about the practical aspects of TasP and PrEP implementation in a variety of clinical settings.

An important global deliverable from this summit will be a Consensus Statement outlining key TasP and PrEP implementation recommendations. The document will be disseminated to IAPAC’s 17,000-plus clinician-members in over 100 countries, as well as through our partnerships with national, regional, and international medical and nursing associations worldwide. Click here to request a copy of the Consensus Statement.